Current Treatment Strategies and Future Treatment Options for Dravet Syndrome

  • Julie Ziobro
  • Krista Eschbach
  • Joseph E. Sullivan
  • Kelly G. KnuppEmail author
Pediatric Neurology (A Yeshokumar, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Pediatric Neurology


Purpose of review

Dravet syndrome is a rare but severe genetic epilepsy that has unique treatment challenges. This is a review of current and future potential treatment options.

Recent findings

Treatment for Dravet syndrome should encompass many aspects of the syndrome such as gait, behavior, and nutrition, as well as focus on seizure control. Many sodium channel blockers should be avoided as they are likely to exacerbate seizures. Current options for treatment include valproic acid, clobazam, stiripentol, and ketogenic diet. Testing is underway for several new treatment options with unique mechanisms of action and therapeutic targets, including the serotonin system and genetic modulation.


Accurate and early diagnosis of Dravet syndrome will lead to avoidance of medications that may exacerbate seizures. Additionally, a multi-disciplinary approach and careful planning for management of episodes of status epilepticus may lead to improved outcomes. Ongoing research for novel approaches to treatment creates optimism for future improvement in outcomes.


Dravet syndrome SCN1A Stiripentol Fenfluramine 


Compliance with Ethical Standards

Conflict of Interest

Kelly G. Knupp reports grants from Zogenix Inc., grants from West Therapeutics, grants from Pediatric epilepsy research fund, personal fees from Stoke therapeutics, and grants from Colorado Department of Public Health, outside the submitted work. Joseph E. Sullivan reports grants from Zogenix, personal fees from Epygenix, and personal fees from Miller Medical, outside the submitted work; and Medical Advisory Board-Dravet Syndrome Foundation. Julie Ziobro and Krista Eschbach each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Wu YW, Sullivan J, McDaniel SS, Meisler MH, Walsh EM, Li SX, et al. Incidence of Dravet syndrome in a US population. Pediatrics. 2015;136:e1310–5. Scholar
  2. 2.
    •• Wirrell EC, Laux L, Donner E, Jette N, Knupp K, Meskis MA, et al. Optimizing the diagnosis and management of dravet syndrome: recommendations from a north american consensus panel. Pediatr. Neurol. 2017. This provides updated consensus recommendations on diagnosis, management of seizures, and management of comorbidities.CrossRefGoogle Scholar
  3. 3.
    Verbeek N, Kasteleijn-Nolst Trenité D, Wassenaar M, van Campen J, Sonsma A, Gunning WB, et al. Photosensitivity in Dravet syndrome is under-recognized and related to prognosis. Clin Neurophysiol. 2017;128:323–30. Scholar
  4. 4.
    Specchio N, Balestri M, Trivisano M, Japaridze N, Striano P, Carotenuto a, et al. Electroencephalographic features in Dravet syndrome: five-year follow-up study in 22 patients. J Child Neurol. 2012;27:439–44. Scholar
  5. 5.
    Brunklaus A, Ellis R, Reavey E, Forbes GH, Zuberi SM. Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain. 2012;135:2329–36. Scholar
  6. 6.
    • Cooper MS, Mcintosh A, Crompton DE, McMahon JM, Schneider A, Farrell K, et al. Mortality in Dravet syndrome. Epilepsy Res. 2016. This is a recent update in mortality in the Dravet population.CrossRefGoogle Scholar
  7. 7.
    Wirrell EC, Laux L, Franz DN, Sullivan J, Saneto RP, Morse RP, et al. Stiripentol in Dravet syndrome: results of a retrospective U.S. study. Epilepsia. 2013;54:1595–604. Scholar
  8. 8.
    De Liso, P., Chemaly, N., Laschet, J., Barnerias, C., Hully, M., Leunen, D., Desguerre, I., Chiron, C., Dulac, O., Nabbout, R.: Patients with dravet syndrome in the era of stiripentol: a French cohort cross-sectional study. Epilepsy Res (2016). doi:, 125, 42, 46.CrossRefGoogle Scholar
  9. 9.
    • Chiron C, Marchand MC, Tran A, Rey E, D’Athis P, Vincent J, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. Lancet. 2000. Trial demonstrating efficacy of stiripentol.CrossRefGoogle Scholar
  10. 10.
    Dressler A, Trimmel-Schwahofer P, Reithofer E, Mühlebner A, Gröppel G, Reiter-Fink E, et al. Efficacy and tolerability of the ketogenic diet in Dravet syndrome - comparison with various standard antiepileptic drug regimen. Epilepsy Res. 2015;109:81–9. Scholar
  11. 11.
    Striano P, Coppola A, Pezzella M, Ciampa C, Specchio N, Ragona F, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology. 2007;69:250–4. Scholar
  12. 12.
    Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia. 1998;39:508–12. Scholar
  13. 13.
    Nabbout R, Chemaly N, Chipaux M, Barcia G, Bouis C, Dubouch C, et al. Encephalopathy in children with Dravet syndrome is not a pure consequence of epilepsy. Orphanet J Rare Dis. 2013;8:176. Scholar
  14. 14.
    Dalic L, Mullen SA, Roulet Perez E, Scheffer I. Lamotrigine can be beneficial in patients with Dravet syndrome. Dev Med Child Neurol. 2015;57:200–2. Scholar
  15. 15.
    de Lange IM, Gunning B, Sonsma ACM, van Gemert L, van Kempen M, Verbeek NE, et al. Influence of contraindicated medication use on cognitive outcome in Dravet syndrome and age at first afebrile seizure as a clinical predictor in SCN1A -related seizure phenotypes. Epilepsia. 2018;59:1154–65. Scholar
  16. 16.
    Morimoto M, Shimakawa S, Hashimoto T, Kitaoka T, Kyotani S. Marked efficacy of combined three-drug therapy (sodium valproate, topiramate and stiripentol) in a patient with Dravet syndrome. J Clin Pharm Ther. 2017;43:571–3. Scholar
  17. 17.
    Katz, R.: Approval package for application number: 203993Orig1s000 (Onfi),
  18. 18.
    Jullien V, Chhun S, Rey E, Dulac O, Tod M, Chiron C, et al. Pharmacokinetics of clobazam and N-desmethylclobazam in children with Dravet syndrome receiving concomitant stiripentol and valproic acid. Clin Pharmacokinet. 2015;54:527–36. Scholar
  19. 19.
    Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58:1586–92. Scholar
  20. 20.
    Peigné S, Chhun S, Tod M, Rey E, Rodrigues C, Chiron C, et al. Population pharmacokinetics of stiripentol in paediatric patients with Dravet syndrome treated with stiripentol, valproate and clobazam combination therapy. Clin Pharmacokinet. 2018;57:739–48. Scholar
  21. 21.
    Myers KA, Lightfoot P, Patil SG, Cross JH, Scheffer IE. Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study. Dev Med Child Neurol. 2018;60:574–8. Scholar
  22. 22.
    Knupp KG, Wirrell EC. Treatment strategies for Dravet syndrome. CNS Drugs. 2018;32:335–50. Scholar
  23. 23.
    Coppola G, Capovilla G, Montagnini A, Romeo A, Spanò M, Tortorella G, et al. Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res. 2002;49:45–8. Scholar
  24. 24.
    Nieto-Barrera M, Candau R, Nieto-Jimenez M, Correa A, Ruiz del Portal L. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure. 2000;9:590–4. Scholar
  25. 25.
    Nabbout R, Copioli C, Chipaux M, Chemaly N, Desguerre I, Dulac O, et al. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia. 2011;52:e54–7. Scholar
  26. 26.
    Wu Q, Wang H, Fan YY, Zhang JM, Liu XY, Fang XY, et al. Ketogenic diet effects on 52 children with pharmacoresistant epileptic encephalopathy: a clinical prospective study. Brain Behav. 2018;8:e00973. Scholar
  27. 27.
    Chhun S, Troude P, Villeneuve N, Soufflet C, Napuri S, Motte J, et al. A prospective open-labeled trial with levetiracetam in pediatric epilepsy syndromes: continuous spikes and waves during sleep is definitely a target. Seizure. 2011;20:320–5. Scholar
  28. 28.
    Inoue S, Yazawa S, Murahara T, Yamauchi R, Shimohama S. Dramatic seizure reduction with levetiracetam in adult Dravet syndrome: a case report. Rinsho Shinkeigaku. 2015;55:151–4. Scholar
  29. 29.
    Dibué-Adjei M, Fischer I, Steiger H-J, Kamp MA. Efficacy of adjunctive vagus nerve stimulation in patients with Dravet syndrome: a meta-analysis of 68 patients. Seizure. 2017;50:147–52. Scholar
  30. 30.
    Dlouhy BJ, Miller B, Jeong A, Bertrand ME, Limbrick DD, Smyth MD. Palliative epilepsy surgery in Dravet syndrome—case series and review of the literature. Childs Nerv Syst. 2016;32:1703–8. Scholar
  31. 31.
    • Devinsky O, Cross J, Laux L, Marsh E, Miller I, Nabbout R, et al. Cannabidiol in Dravet syndrome study group: trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011–20. Trial demonstrating efficacy of cannabidiol in children with Dravet syndrome.CrossRefGoogle Scholar
  32. 32.
    Devinsky O, Patel AD, Thiele EA, Wong MH, Appleton R, Harden CL, et al. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90:e1204–11. Scholar
  33. 33.
    Tang R, Fang F. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;377:699–700. Scholar
  34. 34.
    Porcari GS, Fu C, Doll ED, Carter EG, Carson RP. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: practical experiences in a tertiary medical center. Epilepsy Behav. 2018;80:240–6. Scholar
  35. 35.
    Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:1085–96. Scholar
  36. 36.
    Devinsky O, Patel AD, Cross JH, Villanueva V, Wirrell EC, Privitera M, et al. Effect of Cannabidiol on drop seizures in the Lennox–Gastaut syndrome. N Engl J Med. 2018;378:1888–97. Scholar
  37. 37.
    Iannetti P, Parisi P, Spalice A, Ruggieri M, Zara F. Addition of verapamil in the treatment of severe myoclonic epilepsy in infancy. Epilepsy Res. 2009;85:89–95. Scholar
  38. 38.
    Nicita F, Spalice A, Papetti L, Nikanorova M, Iannetti P, Parisi P. Efficacy of verapamil as an adjunctive treatment in children with drug-resistant epilepsy: a pilot study. Seizure. 2014;23:36–40. Scholar
  39. 39.
    Verbeek, N.E., Wassenaar, M., van Campen, J.S., Sonsma, A., Gunning, B., Knoers, N., Lindhout, D., Jansen, F.E., Leijten, F., Brilstra, E.H., Kasteleijn-Nolst Trenité, D.: Seizure precipitants in Dravet syndrome: what events and activities are specifically provocative compared with other epilepsies? Epilepsy Behav (2015). doi:, 47, 39, 44.CrossRefGoogle Scholar
  40. 40.
    Djémié T, Weckhuysen S, von Spiczak S, Carvill GL, Jaehn J, Anttonen A-K, et al. Pitfalls in genetic testing: the story of missed SCN1A mutations. Mol Genet Genomic Med. 2016;4:457–64. Scholar
  41. 41.
    Fasano A, Borlot F, Lang AE, Andrade DM. Antecollis and levodopa-responsive parkinsonism are late features of dravet syndrome. Neurology. 2014;82:2250–1. Scholar
  42. 42.
    Brunklaus A, Dorris L, Zuberi SM. Comorbidities and predictors of health-related quality of life in Dravet syndrome. Epilepsia. 2011;52:1476–82. Scholar
  43. 43.
    Brunklaus A, Zuberi SM. Dravet syndrome - from epileptic encephalopathy to channelopathy. Epilepsia. 2014;55:979–84. Scholar
  44. 44.
    Knupp KG, Scarbro S, Wilkening G, Juarez-Colunga E, Kempe A, Dempsey A. Parental perception of comorbidities in children with Dravet syndrome. Pediatr Neurol. 2017;76:60–5. Scholar
  45. 45.
    Battaglia, D., Ricci, D., Chieffo, D., Guzzetta, F.: Outlining a core neuropsychological phenotype for Dravet syndrome. Epilepsy Res. Feb, 91–97 (2016). doi:, 120.CrossRefGoogle Scholar
  46. 46.
    Chieffo D, Battaglia D, Lucibello S, Gambardella ML, Moriconi F, Ferrantini G, et al. Disorders of early language development in Dravet syndrome. Epilepsy Behav. 2016;54:30–3. Scholar
  47. 47.
    Rilstone JJ, Coelho FM, Minassian BA, Andrade DM. Dravet syndrome: seizure control and gait in adults with different SCN1A mutations. Epilepsia. 2012;53:1421–8. Scholar
  48. 48.
    Rodda JM, Scheffer IE, McMahon JM, Berkovic SF, Graham HK. Progressive gait deterioration in adolescents with Dravet syndrome. Arch Neurol. 2012;69:873–8. Scholar
  49. 49.
    Licheni SH, Mcmahon JM, Schneider AL, Davey MJ, Scheffer IE. Sleep problems in Dravet syndrome: a modifiable comorbidity. Dev Med Child Neurol. 2018;60:192–8. Scholar
  50. 50.
    Eschbach K, Scarbro S, Juarez-Colunga E, Allen V, Hsu S, Knupp K. Growth and endocrine function in children with Dravet syndrome. Seizure. 2017;52:117–22. Scholar
  51. 51.
    Wallace A, Wirrell E, Kenney-Jung DL. Pharmacotherapy for Dravet syndrome. Pediatr Drugs. 2016;18:197–208. Scholar
  52. 52.
    Schoonheim PJ, Arrenberg AB, Del Bene F, Baier H. Optogenetic localization and genetic perturbation of saccade-generating neurons in zebrafish. J Neurosci. 2010;30:7111–20. Scholar
  53. 53.
    Griffin A, Hamling KR, Knupp K, Hong SG, Lee LP, Baraban SC. Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome. Brain. 2017:aww342.
  54. 54.
    Baraban SC, Dinday MT, Hortopan GA. Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nat Commun. 2013;4:2410. Scholar
  55. 55.
    Zaccara G, Schmidt D. Antiepileptic drugs in clinical development: differentiate or die? Curr Pharm Des. 2018;23:5593–605. Scholar
  56. 56.
    Schoonjans A-S, Marchau F, Paelinck BP, Lagae L, Gammaitoni A, Pringsheim M, et al. Current medical research and opinion cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population. Curr Med Res Opin. 2017;33:1773–81. Scholar
  57. 57.
    Ceulemans B, Boel M, Leyssens K, Van Rossem C, Neels P, Jorens PG, et al. Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia. 2012;53:1131–9. Scholar
  58. 58.
    Ceulemans B, Schoonjans AS, Marchau F, Paelinck BP, Lagae L. Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine. Epilepsia. 2016;57:e129–34. Scholar
  59. 59.
    Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581–8. Scholar
  60. 60.
    Dahl CF, Allen MR, Urie PM, Hopkins PN. Valvular regurgitation and surgery associated with fenfluramine use: an analysis of 5743 individuals. BMC Med. 2008;6.
  61. 61.
    Schoonjans, A.S., Lagae, L., Ceulemans, B.: Low-dose fenfluramine in the treatment of neurologic disorders: experience in Dravet syndrome, (2015).CrossRefGoogle Scholar
  62. 62.
    Wirrell EC. Treatment of Dravet syndrome. Can J Neurol Sci/J Can des Sci Neurol. 2016;43:S13–8. Scholar
  63. 63.
    Lagae L, Sullivan JE, Cross JH, Devinsky O, Guerrini R, Knupp KG, et al. ZX008 (Fenfluramine) in Dravet syndrome: results of a phase 3. Double-Blind, Placebo-Controlled Trial, Randomized; 2017.Google Scholar
  64. 64.
    Orban G, Bombardi C, Marino Gammazza A, Colangeli R, Pierucci M, Pomara C, et al. Role(s) of the 5-HT2C receptor in the development of maximal dentate activation in the hippocampus of anesthetized rats. CNS Neurosci Ther. 2014;20:651–61. Scholar
  65. 65.
    Isaac M. Serotonergic 5-HT2C receptors as a potential therapeutic target for the design antiepileptic drugs. Curr Top Med Chem. 2005;5:59–67. Scholar
  66. 66.
    Venzi M, David F, Bellet J, Cavaccini A, Bombardi C, Crunelli V, et al. Role for serotonin2A (5-HT2A) and 2C (5-HT2C) receptors in experimental absence seizures. Neuropharmacology. 2016;108:292–304. Scholar
  67. 67.
    Grone BP, Qu T, Baraban SC. Behavioral comorbidities and drug treatments in a zebrafish scn1lab model of Dravet syndrome. Eneuro. 2017;4. Scholar
  68. 68.
    Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, Trifillis P, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature. 2007;447:87–91. Scholar
  69. 69.
    Siddiqui N, Sonenberg N. Proposing a mechanism of action for ataluren. Proc Natl Acad Sci. 2016;113:12353–5. Scholar
  70. 70.
    Kosmidis G, Veerman CC, Casini S, Verkerk AO, Van De Pas S, Bellin M, et al. Readthrough-promoting drugs gentamicin and PTC124 fail to rescue Na v 1.5 function of human-induced pluripotent stem cell-derived cardiomyocytes carrying nonsense mutations in the sodium channel gene SCN5A. Circ Arrhythmia Electrophysiol. 2016;9.
  71. 71.
    Ceulemans BPGM, Claes LRF, Lagae LG. Clinical correlations of mutations in the SCN1A gene: from febrile seizures to severe myoclonic epilepsy in infancy. Pediatr Neurol. 2004;30:236–43. Scholar
  72. 72.
    Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet. 2001;68:1327–32. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Julie Ziobro
    • 1
  • Krista Eschbach
    • 2
  • Joseph E. Sullivan
    • 3
  • Kelly G. Knupp
    • 2
    Email author
  1. 1.Division of Pediatric NeurologyUniversity of MichiganAnn ArborUSA
  2. 2.Children’s Hospital ColoradoUniversity of Colorado DenverAuroraUSA
  3. 3.Benioff Children’s HospitalUniversity of California San FranciscoSan FranciscoUSA

Personalised recommendations